Nucleolin as a Potent Biomarker for Predicting Tumor Recurrence among Patients with Hepatocellular Carcinoma after Transplantation
Journal of Gastrointestinal and Liver Diseases · 2025
DOI: 10.15403/jgld-5873 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Gastrointestinal and Liver Diseases, 2025. Verfasst von Guanrong Chen und 13 weiteren Autor:innen. Beteiligte Einrichtung: The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China. . 202211122511253@zcmu.edu.cn. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, RNA-Binding Proteins, Phosphoproteins. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and Aims: Tumor recurrence poses a significant challenge post-liver transplantation (LT) for hepatocellular carcinoma (HCC), necessitating the development of more precise predictive tools. In this study we aimed to investigate nucleolin as a biomarker for predicting HCC recurrence after LT.
Methods
A cohort of 241 HCC patients undergoing LT was enrolled from three medical facilities spanning January 1, 2015, to December 31, 2017. Utilizing tissue microarrays, we assessed the predictive potential of nucleolin. Survival analyses, including Kaplan-Meier and log-rank tests, were employed to scrutinize overall survival and recurrence-free survival. Based on univariate and multivariate Cox regression analyses of preoperative parameters, nomogram and risk score were designed to predict HCC recurrence and determine the effectiveness of the model.
Results
The expression of nucleolin in HCC nucleus was increased. High nucleolin expression in tumor tissues correlated with poor overall survival and recurrence-free survival (5-year overall survival ratios: 34% vs. 64.8%, 5-year recurrence-free survival ratios: 36.1% vs.67.9%, all p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China. . 202211122511253@zcmu.edu.cn.
- Zhejiang University School of Medicine, Hangzhou, China. 12218345@zju.edu.cn.
- The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China. 202311112511113@zcmu.edu.cn.
- Zhejiang University School of Medicine, Hangzhou, China. lihuigang@zju.edu.cn.
- Zhejiang University School of Medicine, Hangzhou, China. 22218489@zju.edu.cn.
- Department of Basic Medicine, Hangzhou Medical College, Hangzhou, China. 2217214270@qq.com.
Zitieren
APA
Chen, G., Hu, X., Huang, Y., Li, H., Dong, L., Jiang, Y., Lu, D., Jiang, F., Li, X., Sun, B., Zheng, S., Lang, R., Xu, X., & Chen, R. (2025). Nucleolin as a Potent Biomarker for Predicting Tumor Recurrence among Patients with Hepatocellular Carcinoma after Transplantation. Journal of Gastrointestinal and Liver Diseases. https://doi.org/10.15403/jgld-5873
Vancouver
Chen G, Hu X, Huang Y, Li H, Dong L, Jiang Y, et al. Nucleolin as a Potent Biomarker for Predicting Tumor Recurrence among Patients with Hepatocellular Carcinoma after Transplantation. Journal of Gastrointestinal and Liver Diseases. 2025. doi:10.15403/jgld-5873
BibTeX
@article{Chen2025,
author = {Chen, Guanrong and Hu, Xin and Huang, Yingchen and Li, Huigang and Dong, Libin and Jiang, Yao and Lu, Di and Jiang, Feng and Li, Xiuyang and Sun, Beicheng and Zheng, Shusen and Lang, Ren and Xu, Xiao and Chen, Ronggao},
title = {Nucleolin as a Potent Biomarker for Predicting Tumor Recurrence among Patients with Hepatocellular Carcinoma after Transplantation},
journal = {Journal of Gastrointestinal and Liver Diseases},
year = {2025},
doi = {10.15403/jgld-5873}
}
EUVIMED